Additional file 6 of PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors

Additional file 6 Pharmaceutical inhibition of PDGFRβ or PKCα activity targets BRCA1 deficient human breast cancer cells. (A, B) HCC1937 (A) and T47D (B) cells treated with DMSO, PDGFR Inh III at 20 nM, or Ro-31-8220 at 35 nM for 24 h were analyzed by western blot. Due to the extremely low level of PDGFRβ and PKCα in T47D cells in comparison with that in HCC1937 cells (shown in Fig. 7b), longer exposure bands for T47D cells were shown in (B). N.S., non-specific band. (C) HCC1937 and T47D cells were treated with DMSO, PDGFR Inh III, or Ro-31-8220 at the indicated concentrations for 24 h, and the number of viable cells was determined. Data are represented as mean ± SD of triplicates. *p < 0.05 between DMSO and drug treated groups by student t test. **p < 0.01 between DMSO and drug treated groups.